Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The overarching goal of this project is to improve the clinical quality of patients with Benzodiazepine-resistant alcohol withdrawal syndrome.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborators: Hospira, Inc.; Hospira, now a wholly owned subsidiary of Pfizer
• Treatments: Diazepam

Criteria

Inclusion Criteria:

either

1. a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs;

2. > 40mg of diazepam (or diazepam equivalents) in 1 hr; or

3. an individual dose of 40 mg or greater of intravenous diazepam for control of agitation

Exclusion Criteria:

• if < 18 years of age or had evidence of use of other illicit substances as determined by urine toxicology screen